Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib with Concurrent Radiotherapy in Unresectable Stage III EGFR-mutant NSCLC
NCT04636593Phase 2Unknown
- Sponsor
- Hangzhou First People's Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Hangzhou First People's Hospital. Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04636593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636593.